Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

246
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
246
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

5.8K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.8K
Health Information Technology and Healthcare Information System01:30

Health Information Technology and Healthcare Information System

922
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
922
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

124
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
124
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

744
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
744
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomonitoring of nutritional and toxic elements in raw and cooked rice in the Health Effects of Arsenic Longitudinal Study, Bangladesh.

Ecotoxicology and environmental safety·2026
Same author

Influenza Antiviral Prescriptions in the US Inpatient and Outpatient Settings During the 2015-2022 Influenza Seasons.

Influenza and other respiratory viruses·2026
Same author

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data.

Health technology assessment (Winchester, England)·2026
Same author

Interplay Between the Gut-Microbiota-Brain Axis and the Immune System in Viral Neuroinvasion and CNS Pathogenesis.

Comprehensive Physiology·2026
Same author

From sensing to shaping: microglial responses in the pathogenesis of viral encephalitis.

Current opinion in immunology·2026
Same author

Cardiac Resynchronization Therapy: A Review.

JAMA·2026

Related Experiment Video

Updated: Sep 12, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.7K

Health Technology Assessment, Again: A Transparent, Evidence-Based Approach For CMS Drug Price Negotiations.

Daniel A Ollendorf1, Leah Z Rand2, Alessandra Blonda3

  • 1Daniel A. Ollendorf (daniel.ollendorf@tuftsmedicine.org), Tufts Medical Center and Tufts University, Boston, Massachusetts.

Health Affairs (Project Hope)
|August 4, 2025
PubMed
Summary

The Centers for Medicare and Medicaid Services (CMS) can now negotiate drug prices. A new framework, based on health technology assessment, is proposed to improve transparency and fairness in future CMS drug price negotiations.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Related Experiment Videos

Last Updated: Sep 12, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Area of Science:

  • Health economics
  • Pharmaceutical policy
  • Health technology assessment

Background:

  • The Centers for Medicare and Medicaid Services (CMS) now has the authority to negotiate prices for high-expenditure Medicare drugs.
  • The success of these negotiations hinges on stakeholder perceptions of transparency and inclusivity.
  • The first round of negotiations for ten drugs is complete, with prices effective January 1, 2026.

Purpose of the Study:

  • To propose an improved framework for future CMS drug price negotiations.
  • To advocate for the adoption of health technology assessment (HTA) best practices.
  • To enhance the transparency, inclusivity, and fairness of the drug price negotiation process.

Main Methods:

  • The proposed framework integrates four key components: selection of therapeutic alternatives, value assessment of selected drugs, a decision matrix for negotiation factors, and deliberation by an independent advisory committee.
  • Patient, caregiver, and stakeholder engagement is a core element throughout the proposed framework.
  • The approach draws upon established health technology assessment methodologies.

Main Results:

  • The abstract does not contain specific results from the first round of negotiations but focuses on a proposed framework for future rounds.
  • The proposed framework aims to provide a structured and evidence-based approach to drug price negotiation.
  • Stakeholder engagement is central to ensuring the legitimacy and acceptance of negotiated prices.

Conclusions:

  • Future CMS drug price negotiations would benefit from adopting a framework grounded in health technology assessment principles.
  • The proposed four-component framework, incorporating stakeholder input, offers a more transparent and equitable approach.
  • Implementing this framework can lead to fairer drug pricing and improved program outcomes.